Candel reports Phase 2 CAN-2409 data: 20.6-month median OS in NSCLC patients with ICI resistance

Candel Therapeutics, Inc.

Median overall survival of 20.6 months in NSCLC patients with progressive disease despite ICI, vs 11.6 months historical SoC docetaxel.
mOS of 22.0 months across all 46 patients with inadequate ICI response.
71.4% of evaluable metastatic patients had beneficial effect on both injected and uninjected tumors (abscopal response).
Increased circulating CD8+ and CD4+ memory T cells after second injection correlated with prolonged survival.
Favorable safety: no grade 4+ TRAEs; three grade 3 events (1 pyrexia, 2 pneumonitis).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.